The study was designed by the sponsor alongside the study investigators. The data were collected by The sponsor and analyzed them with the authors. The first writer wrote the 1st draft of the manuscript. Editorial support was supplied by Articulate Technology and funded by the sponsor. All the authors made a decision to send the manuscript for publication and attest to the precision of the info and analyses reported and for the fidelity of the analysis to the protocol. Research Design The primary objective was to look for the MTD of ceritinib in adult patients with tumors harboring a genetic alteration in ALK. Important secondary objectives were to characterize the safety and side-impact profile, pharmacokinetic profile, and antitumor activity of ceritinib. The analysis included a dose-escalation stage, accompanied by an expansion stage in which all of the patients received treatment at the maximum dose founded in the dose-escalation stage.Vannucchi, E. Papaemmanuil, P.J. Campbell, and A.R. Green: Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2 The myeloproliferative neoplasms are chronic myeloid cancers that are seen as a the overproduction of mature bloodstream cells, and that may evolve into acute myeloid leukemia.1,2 Furthermore to chronic myeloid leukemia with the BCR-ABL fusion gene, the three most common myeloproliferative neoplasms are essential thrombocythemia, polycythemia vera, and myelofibrosis.3-6 The JAK2 V617F mutation or JAK2 exon 12 mutations are located in most individuals with polycythemia vera,7,8 whereas the JAK2 V617F mutation is found in only 50 to 60 percent of patients with essential thrombocythemia or myelofibrosis.9,10 Tests for JAK2 mutations have greatly simplified the diagnosis of myeloproliferative neoplasms and so are now firmly embedded as front-collection tests in national and international guidelines.11-14 However, distinguishing necessary thrombocythemia with nonmutated JAK2 from the much more common reactive thrombocytosis remains a significant diagnostic challenge.